help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ohgaki, H.
Right arrow Articles by Kleihues, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohgaki, H.
Right arrow Articles by Kleihues, P.
(American Journal of Pathology. 2007;170:1445-1453.)
© 2007 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2007.070011

Review

Genetic Pathways to Primary and Secondary Glioblastoma

Hiroko Ohgaki* and Paul Kleihues{dagger}

From the International Agency for Research on Cancer,* Lyon, France; and the Department of Pathology,{dagger} University of Zurich, Zurich, Switzerland

Abstract

Glioblastoma is the most frequent and most malignant human brain tumor. The prognosis remains very poor, with most patients dying within 1 year after diagnosis. Primary and secondary glioblastoma constitute distinct disease subtypes, affecting patients of different age and developing through different genetic pathways. The majority of cases (>90%) are primary glioblastomas that develop rapidly de novo, without clinical or histological evidence of a less malignant precursor lesion. They affect mainly the elderly and are genetically characterized by loss of heterozygosity 10q (70% of cases), EGFR amplification (36%), p16INK4a deletion (31%), and PTEN mutations (25%). Secondary glioblastomas develop through progression from low-grade diffuse astrocytoma or anaplastic astrocytoma and manifest in younger patients. In the pathway to secondary glioblastoma, TP53 mutations are the most frequent and earliest detectable genetic alteration, already present in 60% of precursor low-grade astrocytomas. The mutation pattern is characterized by frequent G:C->A:T mutations at CpG sites. During progression to glioblastoma, additional mutations accumulate, including loss of heterozygosity 10q25-qter (~70%), which is the most frequent genetic alteration in both primary and secondary glioblastomas. Primary and secondary glioblastomas also differ significantly in their pattern of promoter methylation and in expression profiles at RNA and protein levels. This has significant implications, particularly for the development of novel, targeted therapies, as discussed in this review.




This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
F. G. Davis, B. S. Malmer, K. Aldape, J. S. Barnholtz-Sloan, M. L. Bondy, T. Brannstrom, J. M. Bruner, P. C. Burger, V. P. Collins, P. D. Inskip, et al.
Issues of Diagnostic Review in Brain Tumor Studies: From the Brain Tumor Epidemiology Consortium
Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 484 - 489.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Yang, G. Wu, R. F. Barth, M. R. Swindall, A. K. Bandyopadhyaya, W. Tjarks, K. Tordoff, M. Moeschberger, T. J. Sferra, P. J. Binns, et al.
Molecular Targeting and Treatment of Composite EGFR and EGFRvIII-Positive Gliomas Using Boronated Monoclonal Antibodies
Clin. Cancer Res., February 1, 2008; 14(3): 883 - 891.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
S. C. Short, C. Martindale, S. Bourne, G. Brand, M. Woodcock, and P. Johnston
DNA repair after irradiation in glioma cells and normal human astrocytes
Neuro-oncol, October 1, 2007; 9(4): 404 - 411.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Society for Investigative Pathology.